Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sanhuang Jingshiming Pills in Subjects With nAMD
NCT07269769Phase 3Not yet recruiting
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Apr 2026
- Primary completion
- Dec 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Sanhuang Jingshiming in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Tasly Pharmaceutical Group Co., Ltd. Primary endpoint: Proportion of participants with ranibizumab injections at 24 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
Sanhuang Jingshiming
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07269769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07269769.